Postbiotic shows first human evidence of capturing microplastics in the body

Overview

Updated Oct 1

Microplastics have been found in human blood, kidney, and brain tissue, but no one has shown an ingestible product can stop them from getting there. A peer-reviewed study published in Frontiers in Microbiology now reports the first human evidence that a heat-killed probiotic preparation can physically capture plastic particles in the mouth and gut.

Quorum Innovations' Qi601, made from heat-inactivated Limosilactobacillus fermentum, depleted roughly 92% of nanoplastics in simulated digestion and cut nanoplastic entry into human colon cells by 98% in lab tests. A five-person chewing-gum trial showed the material also captures plastic particles released during mastication. Whether this lowers the body's actual plastic burden remains unproven.

Why it matters

An ingestible agent that binds microplastics before absorption could lower the body's plastic burden, though inhaled exposure remains untouched.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

92%

Nanoplastic depletion in simulated digestion

Free nanoplastic fluorescence in supernatant fell ~92% when Qi601 was present during sequential oral, stomach, and intestinal digestion.

98%

Nanoplastic entry blocked into colon cells

Qi601 captured nanoplastics and prevented nearly all of them from entering human Caco-2 colon cells in protection assays.

91%

Rubber particle reduction in human mouth

Background-adjusted rubber-class particle count fell from 2,152 to 185 in saliva when gum chewing included Qi601.

Human proof-of-concept participants

Interventional crossover study in five participants chewing gum with and without Qi601.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Eva Berkes

Lead researcher and medical officer at Quorum Innovations

Led the first-in-human Qi601 study

Martin Wagner

Environmental toxicologist at the Norwegian University of Science and Technology

Public skeptic of the study's real-world limits

Phineas N. Monsul

Co-author and researcher at Quorum Innovations

Co-authored the peer-reviewed study and earlier binding experiments

Organizations Involved

Quorum Innovations Inc.

Biotechnology company

Developer of the Qi601 postbiotic

Sarasota-based biotech developing Qi601 as an ingestible mitigant against dietary micro- and nanoplastics.

Frontiers in Microbiology

Peer-reviewed scientific journal

Published the first-in-human Qi601 study

Open-access microbiology journal that peer-reviewed and published the Qi601 study (DOI 10.3389/fmicb.2026.1881786).

Timeline

2022 September 2026

4 events Latest: September 30th, 2026 · 1 week ago

Tap a bar to jump to that date

September 2026
Peer-reviewed first-in-human study published in Frontiers in Microbiology
Latest Publication

The study was published in Frontiers in Microbiology, reporting the first human in-vivo proof-of-concept that an administered technology can physically capture microplastics. Quorum announced the milestone the same day.
September 30th, 2026
May 2026
Qi601 binding mechanism posted as bioRxiv preprint
Research

The team posted the full study, including simulated digestion, Caco-2 cell protection assays, and the chewing-gum proof-of-concept, as a preprint on bioRxiv.
May 11th, 2026
January 2026
Lab study shows Qi601 binds 98% of nanoplastics in gastric fluid
Research

Atomic force microscopy and gastric-fluid experiments showed Qi601 aggregated nanoplastics on its biofilm surface with 98% binding efficiency in fed-state synthetic gastric fluid.
January 2026
2022
FDA issues GRAS safety notice for Qi601's probiotic strain
Regulatory

The FDA issued Generally Recognized as Safe (GRAS) notice GRN 000988 for heat-inactivated Limosilactobacillus fermentum LfQi6, clearing the safety path for the postbiotic.
2022

Scenarios

Larger trials confirm Qi601 reduces microplastic absorption in the gut

Possible Resolves by Q2 2028

Discussed by: New Scientist, Frontiers in Microbiology authors

Quorum Innovations runs a larger human trial (n>50) that tracks fecal excretion of bound plastics and measures whether Qi601 actually lowers absorbed nanoplastic burden. The current study only showed physical binding in the mouth and cells, not reduced absorption in the body. Success would require demonstrating the bound particles pass through the gut and are excreted rather than retained.

Qi601 reaches the market as a consumer microplastic-mitigation supplement

Likely Resolves by End of 2027

Discussed by: PRNewswire release, industry observers

With GRAS status already secured and early human safety shown, Quorum brings Qi601 to market as a dietary supplement. The company already maintains consumer-facing web properties (Qi601.com, MyGutGuardian.com), suggesting commercialization is planned. The launch would not require a drug approval pathway if marketed as a supplement.

Independent studies find no meaningful real-world benefit under gut conditions

Unlikely Resolves by Q1 2028

Discussed by: Martin Wagner (Norwegian University of Science and Technology), skeptics

Independent labs test Qi601 under realistic conditions — with food present, with the complex gut microbiome and immune cells, and accounting for continuous exposure through food, water, and air. Critics note the current study's lab conditions may not reflect real-world digestive environments. Negative replication would limit the postbiotic to a niche or experimental role.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1940s–present

Lead chelation therapy (mid-20th century)

Doctors began treating heavy-metal poisoning with chelating agents like EDTA, which bind lead and mercury ions in the bloodstream so the body excretes them instead of absorbing them into tissues.

Then

Chelation became the standard emergency treatment for acute lead and mercury poisoning, dramatically reducing mortality and neurological damage.

Now

It established the 'capture-before-absorption' principle for ingestible or injectable binding agents, though chelation's risks limit use to verified poisoning cases.

Why this matters now

Qi601 applies the same capture-before-absorption principle to microplastics — bind the contaminant so the gut never absorbs it. Chelation's history shows both the promise and the limits of this approach: efficacy requires proof the bound material actually passes through the body.

1800s–present

Activated charcoal as emergency poison antidote (19th–20th century)

Physicians used activated charcoal to bind ingested toxins in the gastrointestinal tract, preventing their absorption into the bloodstream. The treatment remains standard for many poisonings.

Then

Activated charcoal became a frontline emergency treatment, binding a wide range of toxins before they reached the bloodstream.

Now

It validated that non-living, ingestible materials can sequester harmful substances in the gut — the same mechanism Qi601 claims for plastics.

Why this matters now

Qi601 is a modern, targeted version of the charcoal principle: a non-living ingestible material that binds contaminants in the digestive tract. Charcoal's long clinical history shows this class of intervention can work, but also that efficacy must be proven for each specific contaminant.

1996–2000s

Olestra fat substitute (1996)

Procter & Gamble launched Olestra, a non-digestible fat substitute that passed through the body unabsorbed, marketed as a zero-calorie cooking oil. The FDA approved it in 1996 despite concerns about gastrointestinal side effects.

Then

Olestra caused cramping and anal leakage in some consumers, and sales collapsed after negative publicity despite FDA approval.

Now

It became a cautionary tale about ingestible products that alter digestion — any new gut-binding agent faces scrutiny over gastrointestinal side effects.

Why this matters now

Qi601, like Olestra, is an ingestible material engineered to interact with gut contents rather than be absorbed. Olestra's history of GI side effects highlights the tolerability questions any new gut-binding supplement will face before broad acceptance.